Palmoplantar Pustulosis Market
Report ID: SQMIG35I2948
Report ID: SQMIG35I2948
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2948 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
116
|Figures:
77
Global Palmoplantar Pustulosis Market size was valued at USD 482.50 Million in 2024 and is poised to grow from USD 516.37 Million in 2025 to USD 885.40 Million by 2033, growing at a CAGR of 7.0% during the forecast period (2026-2033).
The global palmoplantar pustulosis market trends is experiencing growth due to increased incidents of palmoplantar pustulosis driven by an aging population and an increasing number of chronic inflammatory skin conditions, which is increasing the need for more effective treatment options. The majority of treatments available for palmoplantar pustulosis are limited to topical corticosteroids and phototherapy, but the use of systemic agents began in earnest in the early 2000s when clinicians became aware of the condition's effect on quality of life and work productivity. The healthcare systems in Europe and Japan began allocating funds to develop specialized dermatology clinics, which led to the establishment of new markets.
As a result, the palmoplantar pustulosis market has transitioned from a niche market comprised primarily of generic topical agents to an expansive marketplace that provides a full range of treatment options, including biologics, small molecules, and diagnostic tests. These developments underscore the palmoplantar pustulosis market growth in clinical and economic importance. The most recent catalyst for the opened markets is the rapid commercialization of targeted biologic therapy in conjunction with access to favorable reimbursement policies that together generate a virtuous circle of utilization and innovation. Physicians are now able to provide patients with long-term remission with interleukin-23 and interleukin-17 inhibitors as they receive regulatory approval, thereby reducing the frequency and the hospitalizations. This ultimately contributes to a greater willingness among payers to provide coverage for these very expensive treatments.
How is AI Impacting Diagnosis and Treatment Strategies in the Palmoplantar Pustulosis Market?
Clinicians are using artificial intelligence to identify palmoplantar pustulosis market share and select treatments. Machine learning algorithms assess skin images at high resolution, detecting pustular patterns that are not visible with the unaided eye. Predictive models combine patient medical history, smoking history, and genetic testing results to recommend the use of the most effective biological or systemic agent without using trial and error to prescribe a particular medication. In addition, artificial intelligence will speed up target identification by examining large molecular datasets in support of companies needing to prioritize candidates, including IL-23 inhibitors. Artificial intelligence is also assisting in matching eligible subjects with clinical studies to verify therapeutic candidates through real-time analytics, ultimately reducing the time needed for drug development.
Overall, these solutions will enhance clinician confidence in their diagnostics, tailor medications to individual patients, and provide increased efficiency within the marketplace. MoonLake has received Fast Track designation from the FDA for sonelokimab as of February 2026, providing additional treatment options and accelerating growth in the palmoplantar pustulosis marketplace.
Market snapshot - (2026-2033)
Global Market Size
USD 482.5 Million
Largest Segment
Topical Corticosteroids
Fastest Growth
Systemic Retinoids
Growth Rate
7.02% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global palmoplantar pustulosis market is segmented by treatment type, severity, distribution, end-user and region. Based on treatment type, the market is segmented into topical corticosteroids, phototherapy (PUVA), systemic retinoids and biologics (IL-17, IL-23 inhibitors). Based on severity, the market is segmented into mild-moderate and severe. Based on distribution, the market is segmented into hospital pharmacies and specialty pharmacies. Based on end-user, the market is segmented into dermatology clinics and hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Healthcare providers prefer more effective therapies that target inflammatory pathways in patients, they tend to use biologic therapies (anti-IL-17 and -IL-23 therapies) over topical steroid medications to treat PPP. The rapid symptomatic relief and durable dermal responses provided by these agents help to build clinician confidence and increase their use. With an innovative mechanism of action, these biologics decrease dependence on topical steroids, thus improving patient quality of life, providing physicians with a strong incentive to continue to prescribe these products across specialty areas of dermatology. These prerogatives drive these products’ market dominance.
Conversely, topical steroid therapies are growing at the fastest rate out of all of the approved pharmacotherapeutic classes due to their inexpensive and convenient method of treating patients with newly developed PPP. Continuous innovation in various topical steroid formulations has improved skin penetration and reduced the potential for common side effects, satisfying the needs of patients who may be reluctant to receive injectable therapies. Because of their availability, topical steroids have increased the likelihood of widespread use and increased total market size.
The severe segment is by far the largest and most active segment. Patients with serious lesions have severe pain, have functional limitations, and are the patients that clinicians typically choose to use the most powerful treatments on because of their incredible need to have their disease treated quickly through rapid disease control. The use of high potency systemic agents and new biological therapy has become essential to attaining a meaningful remission due to the urgency for treatment; therefore, clinical oversight plays a role in establishing the market leader in this segment. Hospitals usually give priority to these patients by providing them with specialised nursing staff and monitoring for optimal results.
The mild-moderate segment has been growing rapidly due to increased acceptance of early intervention strategies by dermatologists. New topical formulations and phototherapy methods that are patient friendly will significantly reduce the risk of disease progression and the adverse side effects experienced by patients. This trend towards early management of the disease will allow for more patients to be willing to use these treatment options creating an ever-expanding need for accessible treatment options.
To get detailed segments analysis, Request a Free Sample Report
North America holds the largest share of the marketplace due largely to its convergence of excellent medical infrastructure, high levels of clinical awareness, and established reimbursement systems that help patients get access to new treatments. There are extensive research networks in the region, coupled with a team-based approach to research between universities, pharmaceutical companies, and patient advocacy organizations, that enable innovation in new methods of treatment to be developed continuously. The region also has a mature regulatory structure with expedited review processes for new therapies and dermatologists with expertise, which supports early diagnosis and comprehensive treatment of skin conditions. In addition, North America’s large multinational companies, who have significant capacity to manufacture and distribute products have solidified their position as leaders in the market, thereby helping to maintain North America in an influential role in the worldwide marketplace.
Palmoplantar pustulosis market outlook in United States is characterized by a highly developed therapeutic ecosystem supported by leading research hospitals and a sizable patient population that benefits from comprehensive insurance coverage. The emphasis on precision medicine and personalized treatment plans encourages the adoption of emerging biologic agents, while ongoing clinical trials foster a pipeline of innovative therapies. Strong collaborations between academic centers and industry accelerate knowledge exchange, reinforcing the United States as a pivotal hub for market activity and product launches.
Palmoplantar pustulosis market forecast in Canada reflects a well‑structured public healthcare system that ensures equitable access to advanced dermatological care across provinces. National guidelines promote standardized diagnostic pathways, enabling early identification and consistent management of the condition. Collaborative networks between dermatology clinics and research institutions drive the evaluation of novel treatment options, while provincial reimbursement policies support the integration of emerging therapies into clinical practice. This cohesive framework sustains Canada’s role as a significant contributor within the North American market.
The rapid growth of Europe is driven by an increased emphasis on patient-centric care, high levels of clinical research activity and use amenable regulatory frameworks for the prompt implementation of new therapies. Significant government investment in dermatology programs develops a greater awareness of disease and encourages early detection. Cross border partnerships between research institutions, biotechnology companies and clinical networks enable a significant number of targeted therapies to be developed and marketed. In addition, the harmonisation of reimbursement schemes within European health systems grants access to high-cost biologic products and the establishment of specialised dermatology centres with expertise to provide complete care for patients further accelerates the growth of the dermatology market overall in Europe.
Palmoplantar pustulosis market regional outlook in Germany benefits from a sophisticated healthcare framework that emphasizes evidence‑based treatment pathways and a high density of specialized dermatology clinics. Strong collaboration between pharmaceutical companies and academic research centers drives continuous innovation, while national health insurance policies provide broad coverage for cutting‑edge therapies. The presence of leading clinical trial sites further enhances Germany’s capacity to introduce novel agents swiftly, reinforcing its dominant market position.
Palmoplantar pustulosis market regional forecast in United Kingdom is distinguished by swift integration of emerging therapies within the National Health Service, underpinned by comprehensive clinical guidelines that promote early detection. Robust research funding and active participation in multinational trials position the United Kingdom as a frontrunner for rapid market adoption. Collaborative efforts between NHS dermatology networks and biotech firms accelerate pathway approvals, fuelling accelerated market expansion.
Palmoplantar pustulosis market penetration in France is emerging through a supportive public health model that prioritizes dermatological research and patient access to innovative treatments. National health agencies encourage adoption of novel biologics via structured reimbursement pathways. Growing expertise in specialist clinics and active involvement in European research consortia enhance awareness and therapeutic options, contributing to an accelerating market trajectory.
The Asia-Pacific Region is expanding its presence by taking advantage of rapid advances in biotechnological advancements, increasing dermatology networks, and enhancing public awareness of chronic skin disorders among many different ethnic groups. By investing in local R&D capabilities and creating strategic partnerships with multinational pharmaceutical companies to expedite the development and localization of new therapeutics with an emphasis on the growing demographics of the middle class and evolving healthcare infrastructure provides patients access to specialized medical care; while through regulatory reform, streamlines the approval of innovative treatments. Additionally, with the continual focus on digital health platforms and teledermatology, the geographic footprint of Asia-Pacific is expanded, establishing a more inclusive market; providing further opportunity for Asia-Pacific to establish itself as a growing presence globally.
Palmoplantar pustulosis market analysis in Japan is supported by a highly organized healthcare system that emphasizes meticulous clinical practice and early disease identification. Strong collaboration between leading dermatology hospitals and biotech innovators accelerates the introduction of targeted therapies. Governmental health insurance ensures widespread coverage for advanced treatments, while ongoing investment in biomedical research sustains a robust pipeline of emerging solutions, reinforcing Japan’s growing influence in the regional market.
Palmoplantar pustulosis industry trends in South Korea thrives on a dynamic medical ecosystem characterized by swift regulatory approvals and a proactive approach to adopting cutting‑edge dermatological treatments. Integration of innovative biologics into national health coverage, coupled with a high concentration of specialized dermatology clinics, facilitates comprehensive patient management. Strong alliances between local pharmaceutical firms and international research entities promote continuous development of novel therapeutic options, enhancing South Korea’s strategic position within the Asia Pacific market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness Among Dermatologists
Advancements In Biologic Therapies
High Cost Of Treatment Options
Limited Epidemiological Data Availability
Request Free Customization of this report to help us to meet your business objectives.
The palmoplantar pustulosis market is characterized by strong competition among leading pharmaceutical companies focused on expanding their dermatology and immunology portfolios through strategic collaborations, research investments, and pipeline advancements. Companies such as Pfizer and AbbVie continue to strengthen their market positions by developing innovative therapies and pursuing opportunities in inflammatory skin diseases. The growing emphasis on biologic treatments remains a key market driver, with advancements in targeted therapies helping to improve treatment outcomes and broaden therapeutic options for patients. Regulatory designations and clinical progress for emerging biologics are further accelerating innovation and enhancing the competitive landscape.
Top Player’s Company Profile
Recent Developments in the Palmoplantar Pustulosis Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, growing awareness among dermatologists fuels early diagnosis and expands demand for advanced therapies, while the high cost of treatment remains a significant restraint limiting patient uptake in price‑sensitive markets. North America dominates the market thanks to its robust healthcare infrastructure, strong reimbursement mechanisms and active research ecosystem. The biologics segment, especially IL‑17 and IL‑23 inhibitors, leads the market as clinicians favor targeted immunomodulation for rapid symptom relief. A second driver is the rapid commercialization of new biologic agents supported by favorable reimbursement frameworks, which together accelerate adoption and reinforce the region’s leadership and create opportunities for further investment.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 482.5 Million |
| Market size value in 2033 | USD 885.4 Million |
| Growth Rate | 7.02% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Palmoplantar Pustulosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Palmoplantar Pustulosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Palmoplantar Pustulosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Palmoplantar Pustulosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Palmoplantar Pustulosis Market size was valued at USD 482.5 Million in 2024 and is poised to grow from USD 516.37 Million in 2025 to USD 885.4 Million by 2033, growing at a CAGR of 7.02% during the forecast period (2026-2033).
The palmoplantar pustulosis market is shaped by intense competition among major pharma players such as Pfizer and AbbVie, who are leveraging strategic partnerships and pipeline acquisitions to expand their biologics portfolios. A key driver is the pursuit of innovative biologic therapies, illustrated by GSK’s sonelokimab receiving FDA Fast Track status, accelerating market entry and differentiating product offerings. 'Novartis AG (Cosentyx)', 'Eli Lilly (Taltz)', 'AbbVie Inc. (Skyrizi)', 'Johnson & Johnson (Tremfya)', 'UCB SA (Bimzelx)', 'Boehringer Ingelheim (Spevigo)', 'LEO Pharma', 'Galderma SA', 'Almirall SA', 'Sun Pharmaceutical', 'Bristol Myers Squibb', 'Amgen Inc. (Otezla)', 'Janssen (J&J)', 'Kyowa Kirin', 'Maruho Co. Ltd.', 'Mitsubishi Tanabe Pharma', 'Taiho Pharmaceutical', 'Torii Pharmaceutical', 'Sato Pharmaceutical', 'Pola Pharma'
Increased awareness among dermatologists has led to earlier recognition of palmoplantar pustulosis, prompting clinicians to consider targeted therapeutic options. This growing familiarity encourages referrals to specialty centers where comprehensive management protocols are available, thereby expanding patient access to advanced treatments. Moreover, heightened professional education fosters confidence in prescribing emerging biologic agents, supporting broader market uptake. As physicians become more proactive in identifying disease patterns, the overall demand for effective interventions is stimulated, contributing positively to market expansion in clinical practice.
Biologic Therapy Expansion: Biologic agents are increasingly adopted as first‑line interventions for palmoplantar pustulosis, driven by their demonstrated efficacy in reducing lesion severity and improving patient quality of life. Dermatologists are shifting prescribing habits toward targeted immunomodulators, supported by growing clinical confidence and streamlined regulatory pathways. As manufacturers introduce next‑generation biologics with extended dosing intervals, healthcare systems anticipate lower administration burdens and enhanced adherence, fostering broader market penetration across both specialist and primary care settings and encouraging more sustainable long‑term treatment strategies outcomes.
Why does North America Dominate the Global Palmoplantar Pustulosis Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
